<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50131">5-Aza-2'-deoxycytidine</z:chebi> (5-AZA-CdR, <z:chebi fb="0" ids="50131">decitabine</z:chebi>), an epigenetic drug that inhibits DNA methylation, is currently used to treat <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and is under investigation for treating <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and other <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>5-AZA-CdR can reactivate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes silenced by aberrant DNA methylation, a frequent event in <z:hpo ids='HP_0000001'>all</z:hpo> types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Because this epigenetic change is reversible, it is a good target for 5-AZA-CdR therapy </plain></SENT>
<SENT sid="3" pm="."><plain>We have reviewed the preclinical data of 5-AZA-CdR to analyze the concentrations and exposure times required to eradicate <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cells </plain></SENT>
<SENT sid="4" pm="."><plain>We analyzed the dose-schedules used in animal models that show potent <z:chebi fb="0" ids="35610">antineoplastic</z:chebi> activity of 5-AZA-CdR </plain></SENT>
<SENT sid="5" pm="."><plain>We attempted to correlate the preclinical data with the responses obtained in clinical trials of 5-AZA-CdR in patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The pharmacokinetics and drug distribution of 5-AZA-CdR are key parameters because adequate therapeutic drug levels are required to eliminate <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cells in <z:hpo ids='HP_0000001'>all</z:hpo> anatomic compartments </plain></SENT>
<SENT sid="7" pm="."><plain>The plasma half-life of 5-AZA-CdR in humans is approximately 20 minutes due to the high levels in the liver of <z:chebi fb="0" ids="17562">cytidine</z:chebi> deaminase, the enzyme that inactivates this analogue </plain></SENT>
<SENT sid="8" pm="."><plain>This provides a rationale to use an inhibitor of <z:chebi fb="0" ids="17562">cytidine</z:chebi> deaminase in combination with 5-AZA-CdR </plain></SENT>
<SENT sid="9" pm="."><plain>Low-dose 5-AZA-CdR is effective for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and can induce complete remissions (CR) </plain></SENT>
<SENT sid="10" pm="."><plain>However, maintenance of CR with low-dose 5-AZA-CdR is difficult </plain></SENT>
<SENT sid="11" pm="."><plain>Based on analyses of preclinical and clinical data, low dose 5-AZA-CdR has the potential to be an effective form of therapy in some patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>For patients who do not respond to low dose therapy we recommend dose-intensive treatment with 5-AZA-CdR </plain></SENT>
<SENT sid="13" pm="."><plain>Patients who are candidates for intensive dose 5-AZA-CdR should have a good bone marrow status so as to permit adequate recovery from <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e>, the major toxicity of 5-AZA-CdR </plain></SENT>
<SENT sid="14" pm="."><plain><z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">Solid tumors</z:e> are also interesting targets for therapy with 5-AZA-CdR </plain></SENT>
<SENT sid="15" pm="."><plain>Both low dose and intensive therapy with 5-AZA-CdR can reduce the proliferative potential of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stem cells in animal models </plain></SENT>
<SENT sid="16" pm="."><plain>We propose novel dose schedules of 5-AZA-CdR for investigation in patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="17" pm="."><plain>The full chemotherapeutic potential of 5-AZA-CdR to treat <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> merits further clinical investigation and can only be realized when its optimal dose-schedule is determined </plain></SENT>
</text></document>